

To: Ms. Mandisa Hela  
The Registrar of Medicines  
Medicines Control Council  
Private Bag X828  
Pretoria 0001  
Per email: [helam@health.gov.za](mailto:helam@health.gov.za)  
Per fax: +27 12 395 9201

30 October 2014

Dear Ms. Hela:

We, the undersigned clinicians, health care providers, DR-TB patients, and civil society organisations, commend the Medicines Control Council (MCC) on its June 26<sup>th</sup>, 2014 decision, granting Doctors Without Borders (MSF) authorisation to use a generic linezolid product in treatment regimens for selected patients with drug-resistant tuberculosis (DR-TB) in Khayelitsha, Western Cape<sup>1</sup>. This is an important first step toward expanding access to linezolid for DR-TB patients in South Africa. However, **we urge the MCC to immediately register the same generic linezolid product currently under a fast-track review, in order to ensure linezolid is available for all DR-TB patients in need across the country.**

The MSF application under section 21 of the *Medicines and Related Substances Act 101 of 1965* (“the Act”) was based on the unaffordability of the brand name product, Zyvoxid. Prior to the MCC authorisation, MSF purchased Zyvoxid at the exorbitant private sector price of over R700 per 600mg tablet. The cost of this single drug consumed over 10% of the annual MSF operational budget for HIV and TB programmes in Khayelitsha, limiting the number of patients to whom linezolid could be offered. The generic product from manufacturer, Hetero, is purchased by MSF at less than R80 per tablet—a price reduction of over 88%—and provided in terms of the section 21 authorisation from the MCC.

Other clinicians in South Africa are also struggling to offer linezolid to all patients who might benefit from the drug’s use, due to the unaffordability of Zyvoxid. Patients who must access Zyvoxid through the private sector are finding it is not covered by their medical aid due to the high cost, and they cannot afford it on an out-of-pocket basis.<sup>2</sup>

The MCC granted MSF section 21 authorisation after confirming the Hetero product’s approval by the United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA)—a stringent drug regulatory authority and fellow member of the Pharmaceutical Inspection Co-operation Scheme (PIC/S). The same product dossier was submitted to the MCC for full registration in South Africa on the 29 April 2013, and granted fast-track approval status on 6 June 2013. Hetero made a full submission in this regard to the MCC on the 12 June 2013, after which the MCC should have supplied a decision within nine months, in line with Regulation 5 of the General Regulations made in terms of the Act. Over 16 months have now passed, with no decision concerning the application for registration reaching Hetero, to our knowledge.

---

<sup>1</sup> <https://www.msf.org.za/msf-publications/more-msf-patients-with-dr-tb-gain-access-to-dramatically-cheaper-version-life>

<sup>2</sup> <http://www.health-e.org.za/2014/10/03/xdr-tb-patients-smuggle-pills-treatment-priced-reach/>

**It is unclear to the parties signing this letter why the MCC deems the generic product of sufficient quality for MSF to use, but has not yet fully registered the drug.** Full registration of one or more quality generics would allow the National Department of Health to open a more competitive tender and obtain a more affordable linezolid product to address the huge public health impacts of the TB epidemic. It would allow clinicians across South Africa to have fewer concerns for cost when prescribing linezolid to DR-TB patients in need, in line with national guidelines. **Most importantly, the availability of generic linezolid would help save DR-TB patients' lives.**

Clinicians across South Africa consistently struggle to offer adequate treatment regimens for patients with DR-TB. The current treatment course for DR-TB is at least two years, and patients sometimes take more than 20 pills per day and suffer painful injections for the first six months of treatment. The only medicines available can have devastating side effects—including deafness and psychosis—and the cost of a treatment regimen is significantly higher than that for standard, drug-sensitive TB.

World Health Organisation<sup>3</sup> and national<sup>4</sup> guidelines in South Africa recommend linezolid as a third-line drug for DR-TB treatment, when cost permits. These guidelines highlight the importance of linezolid in designing treatment regimens strong enough to combat extensively drug-resistant TB (XDR-TB) and pre-XDR TB. The drug is also one of few available options for patients who do not tolerate standard DR-TB therapies. We estimate that every year, at least 1,000 patients diagnosed with DR-TB in South Africa would be eligible candidates for a linezolid-containing regimen, if cost were not a prohibitive factor. For DR-TB patients, access to an adequate regimen means the difference between life and death.

Earlier this year, the sinister intentions of the multinational pharmaceutical industry to block access to generic medicines were made glaringly obvious. Documents leaked to the media revealed a US\$600,000 plot by 25 multinational pharmaceutical companies to protect profit margins at the expense of public health, by delaying reform of South Africa's patent laws through a covert campaign.<sup>5</sup> In order to counter the corporate interests exposed during "Pharmagate," strong leadership that promotes access to medicines and advances the constitutional right to access healthcare services in South Africa is required from state bodies like the MCC. Registration of generic linezolid would be a clear step forward in the right direction, and help address a disease and public health emergency that is the leading cause of death in South Africa. Further delays in registering a quality-approved generic are unconscionable.

We urge the MCC to register generic Hetero linezolid as a matter of urgency, or to provide urgent clarification on why registration is being delayed. We look forward to your prompt response.

Sincerely,

**Current and Former DR-TB Patients Who Have Benefitted from the Inclusion of Linezolid in their Treatment Regimens**

Phumeza Tisile—Khayelitsha, Western Cape  
Andaleeb Rinquest—Cape Town, Western Cape  
Morgan Scholtz—Kleinkranz, Western Cape  
Mary McNally—Cape Town, Western Cape

---

<sup>3</sup> [http://whqlibdoc.who.int/publications/2011/9789241501583\\_eng.pdf?ua=1](http://whqlibdoc.who.int/publications/2011/9789241501583_eng.pdf?ua=1)

<sup>4</sup> <http://www.hst.org.za/sites/default/files/TBpolicy.pdf>

<sup>5</sup> <http://keionline.org/node/1908>

**Organisations:**



**St.Lukes Hospice\*** (NPC)  
Accredited to the Hospice Palliative Care Association



(Doctors Without Borders South Africa)

**Clinicians and Care Providers**

Priscilla Nelson  
Chief Executive Officer  
St Luke's Hospice  
Kenilworth

Tom Boyles  
Division of Infectious Diseases and HIV Medicine  
Department of Medicine  
University of Cape Town

Dr Elizabeth Augustine  
Kuyasa Clinic

Khayelitsha, City of Cape Town

Dr Beth Harley  
Medical Officer: HIV/STI/TB,  
City Health, Cape Town Municipality

Graeme Meintjes,  
Infectious Diseases Specialist and Associate Professor of Medicine  
University of Cape Town

Dr Natacha Berkowitz,  
Medical Officer Khayelitsha Sub District  
City of Cape Town

Dr. Helen Cox  
Division of Medical Microbiology and Institute for Infectious Disease and Molecular  
Medicine  
University of Cape Town

Dr R Greyling  
TB/HIV CMO, Khayelitsha  
Matthew Goniwe Clinic  
City of Cape Town

Mark Nicol  
Professor and Head, Division of Medical Microbiology,  
University of Cape Town and National Health Laboratory Service

Rabia Cariem  
Medical Officer,  
City of Cape Town

Dr Melissa Budge  
Groote Schuur Hospital  
City of Cape Town

Dr Hanneljie Ferreira  
Medical Officer  
MDR/XDR TB Unit, Tshepong Hospital  
Klerksdorp

Dr. Andrew Black  
DR-TB Physician  
Johannesburg

Dr Yolande Theron  
Kheth'Impilo NGO

Anneke C. Hesselning  
Professor in Paediatrics and Director: Paediatric TB Research Program  
Desmond Tutu TB Centre  
Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences,  
Stellenbosch University

Professor H. Simon Schaaf  
Professor in Paediatrics  
Desmond Tutu TB Centre  
Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences,  
Stellenbosch University

Anthony Garcia-Prats  
Paediatrician and Research Clinician  
Desmond Tutu TB Centre  
Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences,  
Stellenbosch University

Keertan Dheda, MBBCh (Wits), FCP(SA), FCCP, PhD (Lond), FRCP (Lond)  
Professor of Medicine  
Director: Lung Infection and Immunity Unit;  
Head: Division of Pulmonology  
Department of Medicine  
University of Cape Town, & Groote Schuur Hospital

Emma Carkeek  
Medical Officer for City of Cape Town  
Khayelitsha, Cape Town

Linda Aldum  
Senior medical officer  
Tygerberg\Northern

Daliwonga Siganga  
Drug Resistant TB Professional Coordinator  
Mitchell's Plain Sub-District

Carol Cragg  
HAST medical Officer  
Khayelitsha/Eastern substructure  
Metro District Health Services  
Cape Town

Raakhee Girran  
Senior medical officer  
City of Cape Town

Dr Julian te Riele  
Clinical Manager  
Brooklyn Chest Hospital

Dr John Black  
Infectious Diseases Department  
Livingstone Hospital

Paul Willcox  
Emeritus Professor  
Department of Medicine  
University of Cape Town

Dr. Nesri Padayatchi  
CAPRISA

Dr David Stead  
Infectious diseases physician  
New Somerset Hospital  
Cape Town

Rob Warren  
South African Medical Research Council  
Stellenbosch University

Dr A Houston  
Michael Maphongwana CHC  
Khayelitsha, W. Cape

Jason E. Farley, PhD, MPH, NP, FAAN

Associate Professor, Johns Hopkins University School of Nursing  
Adjunct Associate Professor, University of KwaZulu Natal (UKZN), South Africa  
Adult Nurse Practitioner, JHU School of Medicine

Dr. M Biersteker  
Medical Officer  
Michael Maphongwana CHC

**Fort Grey TB Hospital (M/XDR TB Unit), Eastern Cape Dept. of Health**

Dr Lindelwa Cindi - Clinical Manager  
Dr Oluwade Olaborede - Medical Officer  
Dr Mfundiso Ntlola - Medical Officer  
Dr Mzondeleli Mashicila - Medical Officer

**King Dinuzulu Hospital Complex (central MDR/XDR-TB hospital in KwaZulu Natal)**

Dr. K. Naidu  
Dr. S. Chotoo  
Dr. L. Pather  
Dr. J. Maharaj  
Dr. S. Nazeer  
Dr. V.S. Challa  
Dr. V.B. Sunkari  
Dr. N. Singh  
Dr. R. Czarnocki  
Dr. D. Zitha  
B.V Shezi (PN)  
M.M Ngobese (EN)  
Dr. S.B Maharaj  
N. Misra (Pharmacist)  
Z. Zondi (Pharmacist)  
Dr. G.R Loganathan  
M. Zulu (EN)  
T. Shozi (PN)  
Mavis Dlamini  
W. Ngcobo  
C. Zungu  
B. Mthethwa  
S.T Sithole  
Dr. A.N Gwala  
Dr. A.S Pala  
Dr. S. Khalid  
Dr. L.G Osburn  
P.M. Radebe (PN)

S. Naidoo  
G. Lutchmanan  
M.C. Mkhize  
J.L. Mhlongo  
D.T. Khumalo  
T.N. Mpanza  
P.B. Mbanjwa  
S.P. Mageba

**Doctors Without Borders South Africa, Eshowe Project, Kwa-Zulu Natal**

Mercy Munduru  
Roderick R Embuido  
Kyaw Soe Htet  
Matthew Reid  
Teresa Sebastiani  
Vilaphi Bhengu

**Doctors Without Borders South Africa, Khayelitsha Project, Western Cape**

Dr. Vivian Cox  
Dr. Jennifer Hughes  
Dr. Aurelie Nelson  
Dr. Jonathan Bernheimer  
Lynne Wilkinson  
Dr. Mary Ibeto  
Vuyo Valkala  
Leigh Snyman  
Ruth Henwood  
Gabriela Patten  
Juliet Joubert  
Iain Watermeier